Skip to content


  • Meeting abstract
  • Open Access

Second hit influences the interaction between tumor cells and the immune system in a murine model of Burkitt's lymphoma

  • 1,
  • 2,
  • 1,
  • 1,
  • 3,
  • 2,
  • 1 and
  • 1, 4Email author
BMC Pharmacology20088 (Suppl 1) :A21

  • Published:


  • Tumor Cell
  • Immune System
  • Survival Advantage
  • Genetic Lesion
  • Haematological Tumor

The process of cancerogenesis is driven by the hierarchical accumulation of genetic changes. So, beside the deregulated expression of an oncogen, additional genetic defects have to take place in order to transform a normal cell into a tumor cell. In case of Burkitt's lymphoma, a c-myc-driven haematological tumor, two predominant so called 2nd hits have been identified. First, loss-of-function mutations in the p19-Mdm2-p53 tumor suppressor pathway, and second, the over-expression of the anti-apoptotic protein Bcl-2. So far it is not known whether these two different 2nd hits translate into cell-autonomous effects or the ability of the immune system of recognizing and destroying the tumor cells. Our studies revealed that neither over-expression of Bcl-2 nor loss-of-function mutations in the p19-Mdm2-p53 tumor suppressor pathway alters any analysed cell-autonomous effect significantly. However, we could specify an impact of these additional genetic lesions on the interaction between immune system and tumor cells. We were able to show that tumor cells over-expressing Bcl-2 can be eliminated by the immune system more effectively than ones with p19-Mdm2-p53 tumor suppressor pathway malfunctions. These data are in line with the analysis regarding 2nd hits of primary tumor samples obtained form an animal model of Burkitt's lymphoma. This analysis showed a clear survival advantage of mice suffering from tumors over-expressing Bcl-2. Taken together, our studies provide basic knowledge concerning the influence of the 2nd hit on the interaction between immune system and tumor cells, which might have prognostic value for immune based cancer therapies.

Authors’ Affiliations

Department of Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
Division of Developmental Immunology, Medical University of Innsbruck, 6020, Austria
Institute of Animal Breeding and Genetics, Veterinary University of Vienna, and Austrian Center for Biomodels and Transgenetics (ÖZBT VUW), 1220 Vienna, Austria
Ludwig Boltzmann Institute for Cancer Research, 1090 Vienna, Austria


© Schuster et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.